Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma-Reference-Cited by-同舟云学术

Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

Published:2023-12-29 Issue:1 Volume:8 Page:219-223
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Paiva Bruno¹^ORCID,Zherniakova Anastasiia¹,Nuñez-Córdoba Jorge M.¹,Rodriguez-Otero Paula¹^ORCID,Shi Qian²,Munshi Nikhil C.³,Durie Brian G. M.⁴,San-Miguel Jesus¹^ORCID

Affiliation:

1. 1Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, Cedars-Sinai Medical Center CB16/12/00369, Pamplona, Spain

2. 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

3. 3Dana-Farber Cancer Institute and Boston VA Healthcare System, Boston, MA

4. 4Cedars-Sinai Medical Center, Los Angeles, CA

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/1/219/2180427/blooda_adv-2023-010821-main.pdf

Reference22 articles.

1. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial;Dytfeld;Lancet Oncol,2023

2. Triplet therapy, transplantation, and maintenance until progression in myeloma;Richardson;N Engl J Med,2022